Anesthesia providers play a critical role in identifying and managing coagulopathy, especially during large-volume transfusions where patients are at risk of developing dilutional coagulopathy, a condition caused by the depletion of clotting factors. Effective management requires close monitoring of the patient's coagulation status to prevent excessive bleeding or thrombosis.
Point-of-Care Testing (POC): Technologies like thromboelastography (TEG) and rotational thromboelastometry (ROTEM) provide real-time, dynamic assessments of the entire coagulation process, from clot formation to clot stability and breakdown. Unlike traditional coagulation tests, which often focus on isolated parameters (e.g., INR, PT, aPTT), POC testing evaluates the functional integrity of clotting factors, platelets, and fibrinogen, offering a more comprehensive view.
Anesthesia providers can tailor transfusion therapy more precisely by using TEG or ROTEM during surgery or massive transfusion scenarios. For example, they can determine whether a patient needs additional platelets, fresh frozen plasma, or fibrinogen, reducing the risk of unnecessary transfusions and associated complications. POC testing also allows for faster decision-making compared to traditional lab results, which may take longer to process.
Clinical Example: In cardiac surgery, where patients are at high risk for bleeding, POC testing using ROTEM can quickly identify fibrinogen deficiency and guide the administration of cryoprecipitate, helping restore coagulation and minimize bleeding.
By leveraging these tools, anesthesia providers can significantly improve patient outcomes and optimize the use of blood products during surgery.
| Aspect | Detail |
|---|---|
| What is assessed | The entire coagulation process, from clot formation through clot stability and breakdown, rather than the isolated parameters of traditional tests such as INR, PT, and aPTT |
| Functional detail | The functional integrity of clotting factors, platelets, and fibrinogen |
| Turnaround | Real-time, dynamic assessment allowing faster decisions than traditional laboratory results, which may take longer to process |
| Product selection | Shows whether the patient needs additional platelets, fresh frozen plasma, or fibrinogen, reducing the risk of unnecessary transfusion |
| Fibrinogen deficiency | In cardiac surgery, ROTEM can quickly identify fibrinogen deficiency and guide administration of cryoprecipitate |
| Effect on product use | A randomized controlled trial found ROTEM-guided transfusion protocols in cardiac surgery reduced blood product usage by 20% without compromising patient safety |
| Where it matters most | Large-volume transfusion, where patients risk dilutional coagulopathy from depleted clotting factors |
